Augment infrastructure to accelerate technology development, validation, and translation.
We build upon the existing research framework at the Biointerfaces and invest in three research cores to aggressively develop and translate technologies that target brain cancer.
Formulation & Translation Core
The core aims to reproducibly develop new drugs, nanoparticle formulations, and prototype devices within a sterile environment for subsequent animal testing. To ensure accurate dosing and sterility, the materials will undergo comprehensive characterization using multiple methodologies. Expert consultations will be conducted to assess the technology and market readiness, as well as determine the regulatory path for the developed innovations. The Core will perform exploratory pharmacokinetics, safety, and biocompatibility assessments of the new technologies. This Core will also focus on demonstrating the broad applicability of these technologies in delivering multiple drugs, establishing scalability in processes, and conducting reproducibility experiments. Furthermore, it will facilitate interactions for intellectual property (IP) protection and support the submission of translational grant applications within the University of Michigan (UM) and government agencies. These efforts will not only enable filing and prosecution of patents but also ensure a comprehensive due diligence process for potential out-licensing opportunities.
Conduct pharmacological evaluation of new technologies and therapeutic preclinical experiments in relevant brain tumor animal models, TME profiling and tumor burden/progression and response to therapeutics. These data will also be used for patents, due diligence and grant applications.
Questions should be sent to the Core Director, Pedro Lowenstein at firstname.lastname@example.org